OBJECTIVE: To determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer disease (AD) in patients with mild cognitive impairment (MCI). METHODS: We stratified 192 MCI participants into positive and negative risk groups on the basis of 1) degree of learning impairment on the Rey Auditory Verbal Learning Test; 2) medial temporal atrophy, quantified from Food and Drug Administration-approved software for automated vMRI analysis; and 3) CSF biomarker levels(.) We also stratified participants based on combinations of risk factors. We computed Cox proportional hazards models, controlling for age, to assess 3-year risk of converting to AD as a function of risk group and used Kaplan-Meier analyses to determine median survival times. RESULTS: When risk factors were examined separately, individuals testing positive showed significantly higher risk of converting to AD than individuals testing negative (hazard ratios [HR] 1.8-4.1). The joint presence of any 2 risk factors substantially increased risk, with the combination of greater learning impairment and increased atrophy associated with highest risk (HR 29.0): 85% of patients with both risk factors converted to AD within 3 years, vs 5% of those with neither. The presence of medial temporal atrophy was associated with shortest median dementia-free survival (15 months). CONCLUSIONS: Incorporating quantitative assessment of learning ability along with vMRI or CSF biomarkers in the clinical workup of MCI can provide critical information on risk of imminent conversion to AD.
OBJECTIVE: To determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer disease (AD) in patients with mild cognitive impairment (MCI). METHODS: We stratified 192 MCI participants into positive and negative risk groups on the basis of 1) degree of learning impairment on the Rey Auditory Verbal Learning Test; 2) medial temporal atrophy, quantified from Food and Drug Administration-approved software for automated vMRI analysis; and 3) CSF biomarker levels(.) We also stratified participants based on combinations of risk factors. We computed Cox proportional hazards models, controlling for age, to assess 3-year risk of converting to AD as a function of risk group and used Kaplan-Meier analyses to determine median survival times. RESULTS: When risk factors were examined separately, individuals testing positive showed significantly higher risk of converting to AD than individuals testing negative (hazard ratios [HR] 1.8-4.1). The joint presence of any 2 risk factors substantially increased risk, with the combination of greater learning impairment and increased atrophy associated with highest risk (HR 29.0): 85% of patients with both risk factors converted to AD within 3 years, vs 5% of those with neither. The presence of medial temporal atrophy was associated with shortest median dementia-free survival (15 months). CONCLUSIONS: Incorporating quantitative assessment of learning ability along with vMRI or CSF biomarkers in the clinical workup of MCI can provide critical information on risk of imminent conversion to AD.
Authors: F H Bouwman; S N M Schoonenboom; W M van der Flier; E J van Elk; A Kok; F Barkhof; M A Blankenstein; Ph Scheltens Journal: Neurobiol Aging Date: 2006-06-19 Impact factor: 4.673
Authors: Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones Journal: Proc Natl Acad Sci U S A Date: 2009-02-19 Impact factor: 11.205
Authors: C Eckerström; U Andreasson; E Olsson; S Rolstad; K Blennow; H Zetterberg; H Malmgren; A Edman; A Wallin Journal: Dement Geriatr Cogn Disord Date: 2010-04-09 Impact factor: 2.959
Authors: Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327
Authors: D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon Journal: Neurology Date: 2007-03-13 Impact factor: 9.910
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: S Gauthier; P S Aisen; S H Ferris; D Saumier; A Duong; D Haine; D Garceau; J Suhy; J Oh; W Lau; J Sampalis Journal: J Nutr Health Aging Date: 2009-06 Impact factor: 4.075
Authors: Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff Journal: Neurobiol Aging Date: 2012-04-13 Impact factor: 4.673
Authors: Nikdokht Farid; Holly M Girard; Nobuko Kemmotsu; Michael E Smith; Sebastian W Magda; Wei Y Lim; Roland R Lee; Carrie R McDonald Journal: Radiology Date: 2012-06-21 Impact factor: 11.105
Authors: K Ambarki; T Lindqvist; A Wåhlin; E Petterson; M J B Warntjes; R Birgander; J Malm; A Eklund Journal: AJNR Am J Neuroradiol Date: 2012-05-03 Impact factor: 3.825
Authors: Selam Negash; Daria Kliot; Darlene V Howard; James H Howard; Sandhistu R Das; Paul A Yushkevich; John B Pluta; Steven E Arnold; David A Wolk Journal: J Int Neuropsychol Soc Date: 2015-05-20 Impact factor: 2.892
Authors: Noll L Campbell; Fred Unverzagt; Michael A LaMantia; Babar A Khan; Malaz A Boustani Journal: Clin Geriatr Med Date: 2013-11 Impact factor: 3.076
Authors: Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust Journal: J Neurosci Date: 2013-03-27 Impact factor: 6.167